Research Article

Dopamine D₂ Receptor-Mediated Heterologous Sensitization of AC5 Requires Signalosome Assembly

Karin F. K. Ejendal, Carmen W. Dessauer, Terence E. Hébert, and Val J. Watts

1 Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907-2051, USA
2 Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
3 Department of Pharmacology Therapeutics, McGill University, McIntyre Medical Sciences Building, Montréal, QC, Canada H3G 1Y6

Correspondence should be addressed to Val J. Watts, wattsv@purdue.edu

Received 7 October 2011; Accepted 28 December 2011

Academic Editor: J. Adolfo García-Sainz

Copyright © 2012 Karin F. K. Ejendal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chronic dopamine receptor activation is implicated in several central nervous system disorders. Although acute activation of Gαs-coupled D₂ dopamine receptors inhibits adenylyl cyclase, persistent activation enhances adenylyl cyclase activity, a phenomenon called heterologous sensitization. Previous work revealed a requirement for Gαs in D₂-induced heterologous sensitization of AC5. To elucidate the mechanism of Gαs dependency, we expressed Gαs mutants in Gαs-deficient GnasE2−/−/E2− cells. Neither Gαs-palmitoylation nor Gαs-Gβγ interactions were required for sensitization of AC5. Moreover, we found that coexpressing βARKct-CD8 or Sar1(H79G) blocked heterologous sensitization. These studies are consistent with a role for Gαs-AC5 interactions in sensitization however, Gβγ appears to have an indirect role in heterologous sensitization of AC5, possibly by promoting proper signalosome assembly.

1. Introduction

Dopamine receptors and dopamine signaling have been implicated in various neurological and psychiatric disorders including Parkinson’s disease, schizophrenia, and drug abuse [1–3]. Dopamine receptors are divided into two subfamilies, the Gαs-coupled D₁ and D₅ receptors and the Gαi/o-coupled D₂, D₃, and D₄ dopamine receptors that have stimulatory and inhibitory effects on adenylyl cyclase (AC), respectively (see [3] for a recent review). Acute stimulation of D₂ dopamine receptors leads to inhibition of AC activity, however, persistent activation of this Gαi/o-coupled receptor paradoxically results in its enhancement [4]. This phenomenon, called heterologous sensitization of AC, is also known as cAMP overshoot, supersensitization, or superactivation of AC. D₂ dopamine receptor-induced heterologous sensitization of cyclic AMP signaling has been demonstrated in several cellular systems as well as in animal models and has also been suggested to occur in humans [4–6]. For example, it was observed that repeated administration of the D₂ receptor agonist quinpirole enhances AC activity in the caudate putamen, increases CREB phosphorylation, and also alters behavior in rodents [5, 6]. Although this mode of AC regulation has been recognized for over three decades [7], the molecular signaling mechanism causing heterologous sensitization of AC is only partially understood, attributed to some extent to differences in AC isoform-specific regulation [4].

There are nine differentially regulated membrane-bound AC isoforms in mammalian cells [4, 8]. Whereas all AC isoforms are stimulated by stimulatory Gαs, only a subset is inhibited by inhibitory Gαi, and some AC isoforms are differentially regulated by Gβγ [4, 8]. Here, we studied human adenylyl cyclase type 5 (AC5) that is potently stimulated by Gαs, inhibited by acute activation of Gαs, and conditionally activated by Gβγ [8]. AC5 is expressed at high levels in the central nervous system and has been identified as a primary effector of D₂ dopamine receptors in the striatum [9, 10].
The aim of the current study was to investigate the role(s) of heterotrimeric G proteins in D₂ receptor-mediated heterologous sensitization of AC5. By exploring sensitization in cells devoid of endogenous Ga₃ [11], we were able to examine the ability of Ga₃ mutants to support sensitization without interference from endogenous Ga₃. Additionally, this Ga₃-defect cell model expresses very low levels of AC5 making them a reasonable model for studies of recombinant AC5 [12]. Heterologous sensitization of AC5 was readily rescued by wild-type Ga₃, and by mutants deficient in palmitoylation [13] or Gi/βγ interaction [14]. We also assessed the role of Gi/βγ and the signalosome in D₂ receptor-induced heterologous sensitization of AC5 by sequestering Gi/βγ subunits with βARKct-CD8 [15, 16] and coexpressing a dominant-negative mutant of the Sar1 GTPase [17]. These experiments revealed that both βARKct-CD8 and Sar1(H79G) attenuated sensitization, suggesting that the components of the signaling complex utilized in heterologous sensitization, presumably AC5 and Ga₃, assemble postsynthesis in the endoplasmic reticulum (ER). Together with previous findings, the present data support a model in which Ga₃ directly interacts with AC5. In contrast, Gi/βγ appears to have an indirect role in heterologous sensitization of AC5.

2. Materials and Methods

2.1. Constructs. The human D₂L receptor and AC5 or ΔAC5 [18] were cloned into the dual expression vector pBUDCE4 (Invitrogen, Carlsbad, CA) creating pBUD/hAC5, D₂R and pBUD/ΔAC5, D₂R. pcDNA3/βARKct-CD8 [15, 16] and pcDNA/vsvg-Sar1 (wild type and H79G) [19] were used. pcDNA1/Ga₃-CFP [20] was a gift from Dr. Catherine Berlot. The pcDNA3.1/Ga₃-IEK+ mutant [21] was a gift from Dr. Philip Wedegaertner. The C3S mutation was created by site-directed mutagenesis, and the fragment containing the IEK+ mutations was amplified by PCR. The resulting constructs, pcDNA1/Ga₃-CFP(C3S) and pcDNA1/Ga₃-CFP(IEK+) were sequenced.

2.2. Cell Culture and Transient Transfection. All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. Ga₃-deficient murine embryonic fibroblast cells, GnasΔE1-E2/ΔE1-E2 cells [11, 12], were a gift from Dr. Murat Bastpe. Cells were cultured in 50:50 mix of F12:DMEM media supplemented with 5% FBS (HyClone, Logan, UT), 1% Anti-Anti (Invitrogen, Carlsbad, CA) in a humidified incubator at 33°C. Approximately 80,000 cells/well were seeded in 24-well plates the day before transient transfection. DNA (400 ng pBUD/hAC5 or ΔAC5, D₂R alone or in combination with 10 ng pcDNA/Ga₃-CFP, 300 ng pcDNA3/βARKct-CD8, or 300 ng pcDNA/vsvg-Sar1) was mixed with Opti-MEM and 1 μL/well Lipofectamine 2000 (Invitrogen, Carlsbad, CA). The medium was replaced with 200 μL/well prewarmed Opti-MEM, and the DNA/Lipofectamine mixture was added to the cells. After 4 hr, culture medium (500 μL/well) was added, and the cells were analyzed after 48 hr. For microscopy, the amount of pcDNA/Ga₃-CFP was increased to 100 ng/well.

2.3. Acute cAMP Accumulation. The assays were carried out in assay buffer (EBSS supplemented with 0.2% ascorbic acid, 15 mM HEPES, and 2% BCS (HyClone, Logan, UT), and 500 μM IBMX) with 100 nM forskolin (Tocris Bioscience, Ellisville, MO) as noted for 37°C for 15 min. The media was decanted, ice-cold trichloroacetic acid was added, and the lysates were stored at 4°C. Cyclic AMP was quantified using a competitive binding assay as described previously [22]. Data were collected from a minimum of three independent experiments carried out in duplicate and were normalized to either basal or vehicle conditions. The GraphPad Prism 5 software (GraphPad Software Inc., LaJolla, CA) was used for data and statistical analyses. A P value of ≤0.05 was considered statistically significant.

2.4. Heterologous Sensitization. The cells were pretreated with 1 μM quinpirole or vehicle in assay buffer (without IBMX) for 2 hr followed by three washes. cAMP was measured as described above for acute cAMP accumulation, with the addition of 1 μM spiperone to block the action of any residual quinpirole.

2.5. Microscopy. Cells were seeded in cover glass slides (Nunc, Rochester, NY). A 12 bit photometric CoolSNAP (Roper Scientific) CCD camera mounted on a TE-2000 inverted epifluorescence microscope (Nikon Instruments Inc., Melville, NY) with filters (ex. 500/20, em. 535/30) from Chroma (Rockingham, VT) was used. Images were acquired with the MetaMorph software (Molecular Devices, Sunnyvale, CA) and analyzed using Image J (http://rsbweb.nih.gov/ij/).

3. Results and Discussion

3.1. Ga₃ Mutants Rescue Heterologous Sensitization of AC5. Our laboratory has previously shown that mutants of canine AC5 that do not interact with Ga₃ are deficient in sensitization [23, 24] and that D₂-mediated heterologous sensitization of AC5 has an absolute requirement for Ga₃ [12]. Our present objective was to elucidate the mechanism of Ga₃-dependent heterologous sensitization of human AC5 by utilizing two different Ga₃-CFP [20] mutants (Figure 1(a)). The C3S substitution eliminates the N-terminal palmitoylation site, which causes Ga₃ to mislocalize to the cytosolic fraction [13]. The IEK+ mutant contains a series of substitutions, yielding a Gi/βγ-binding deficient Ga₃ that also displays a reduction in palmitoylation [21].

The Ga₃-CFP constructs were coexpressed with AC5 and D₂. Since both C3S and IEK+ are deficient in responses to receptor stimulation [13, 21], we used direct stimulation of AC5 with forskolin throughout this study. Basal cAMP accumulation without any Ga₃ was 0.73 ± 0.09 pmol/well, whereas co-expression of Ga₃-CFP increased cAMP accumulation to 3.12 ± 0.22 pmol/well (wild-type, wt), 4.22 ± 0.06 pmol/well (C3S), and 5.88± 0.05 pmol/well (IEK+). Forskolin further stimulated cAMP with values 2.5–3-fold over basal levels (Figure 1(b)), indicating that wild-type and both Ga₃ mutants functionally couple to AC5.
Next, expression and subcellular localization of the G\(\alpha_s\)-CFP mutants were evaluated by fluorescence microscopy (Figure 1(c)). Wild-type G\(\alpha_s\)-CFP showed both plasma membrane and intracellular localization, whereas the C3S and IEK+ mutants were predominantly localized intracellularly (Figure 1(c)), consistent with previous reports [14, 21].

To assess whether the G\(\alpha_s\)-CFP mutants could rescue heterologous sensitization, cells were pretreated with vehicle or quinpirole followed by cAMP accumulation. Consistent with our previous report [12], no sensitization of AC5 was observed in the absence of G\(\alpha_s\) (Figure 1(d), ctrl). In contrast, coexpression of wild-type G\(\alpha_s\)-CFP resulted in robust sensitization of AC5 under both basal and forskolin-stimulated conditions (Figure 1(d)). Surprisingly, expression of the G\(\alpha_s\) mutants also significantly rescued heterologous sensitization under basal conditions (white bars) and to a lesser degree forskolin-stimulated conditions (black bars). As both mutants are deficient in palmitoylation and membrane localization, neither palmitoylation and membrane localization of G\(\alpha_s\) appears to be essential for heterologous sensitization of AC5.

3.2. Role of G\(\beta\gamma\) Subunits in Heterologous Sensitization of AC5.

Although we have established that G\(\alpha_s\) is required for heterologous sensitization, our findings above for the IEK+ mutant suggest that direct interactions between G\(\alpha_s\) and G\(\beta\gamma\) are not critical. This prompted us further to investigate the role of G\(\beta\gamma\) in D\(_2\) receptor-mediated heterologous sensitization of AC5. The C-terminus of \(\beta\)-adrenergic kinase or GRK2 (\(\beta\)ARKct) has been used to sequester G\(\beta\gamma\) subunits and inhibit G\(\beta\gamma\)-mediated signaling events, including heterologous sensitization [15, 25, 26]. In the absence of \(\beta\)ARKct-CD8 (membrane bound \(\beta\)ARKct), AC5 displayed robust heterologous sensitization (open bars, Figure 2(a)). Sequestering G\(\beta\gamma\) blocked sensitization of AC5, under both basal and forskolin-stimulated conditions, revealing the necessity of G\(\beta\gamma\) for heterologous sensitization of AC5 (black bars, Figure 2(a)). In contrast, \(\beta\)ARKct-CD8 had no substantial effects on acute D\(_2\) receptor activation; quinpirole produced significant inhibition of cAMP accumulation in the presence of \(\beta\)ARKct-CD8 (77 ± 10% inhibition; \(n = 2\), data not shown). In an effort to explore the site of action for G\(\beta\gamma\)-dependent sensitization, we used an N-terminal deletion mutant of AC5, \(\Delta\)AC5. This mutant is functional and responds to G\(\alpha_s\) stimulation but is deficient in binding G\(\beta\gamma\) [18]. The \(\Delta\)AC5 mutant displayed significant sensitization that was also blocked by \(\beta\)ARKct-CD8 (Figure 2(b)), suggesting that N-terminal G\(\beta\gamma\) binding is not intimately involved in heterologous sensitization of AC5. Instead, there are clearly additional, unidentified G\(\beta\gamma\) interaction sites in AC5 that are necessary for heterologous sensitization. Such an assumption is supported by FRET and in vitro activation studies of the AC5 deletion mutant [18] as well as studies of AC2, which possesses multiple motifs for G\(\beta\gamma\) interaction and regulation that are located in the C1b and C2b domains of AC2 [27]. Other possibilities are that \(\Delta\)AC5 interacts with endogenous AC isoforms in an AC dimer (see [28]) that binds G\(\beta\gamma\) or that specific G\(\beta\) and G\(\gamma\) subunits or G\(\beta\gamma\) pairs are involved. However, it is also possible that the G\(\beta\gamma\) mechanisms involving sensitization of AC may be indirect [4].

3.3. Disruption of Signalosome Assembly Affects Heterologous Sensitization of AC5.

Because sequestering G\(\beta\gamma\) subunits alters signalosome assembly [15], we hypothesized that a specific signaling complex could be required for heterologous sensitization of AC5. Several small GTPases, including Sar1,
are involved in signal complex assembly and anterograde protein trafficking [29]. A series of studies using dominant negative mutants of these GTPases shows that G\textsubscript{\alpha}s and G\textsubscript{\beta\gamma} interact with AC2 during trafficking to the plasma membrane [30, 31] and that the G\textsubscript{\alpha}s-AC2 interaction is disrupted by Sar1(H79G) [30].

To study the possibility that interactions between AC5 and its specific signaling partners play a role, we utilized Sar1 and Sar1(H79G) and noted that coexpression with the dominant negative mutant prevented heterologous sensitization of AC5 (Figure 2(c)). In contrast, acute D\textsubscript{2} receptor-mediated inhibition of AC5 was not significantly blocked in the presence of Sar1(H79G) (data not shown). Our data are consistent with the findings that Sar1(H79G) disrupts AC-G\textsubscript{\alpha}s interactions (as measured by BRET or coimmunoprecipitation) to a larger degree than AC-G\textsubscript{\alpha}i interactions [30]. In contrast, Sar1(H79G) did not affect the interactions between AC and G\textsubscript{\beta\gamma} [30], suggesting that the AC interacts with G\textsubscript{\beta\gamma} at an early step in the endoplasmic reticulum (ER), but that the interaction with G\textsubscript{\alpha}s occurs after ER export. The observation that signaling mechanisms of acute activity and heterologous sensitization are differentially affected further supports the hypothesis that heterologous sensitization and acute stimulation are dependent on separate mechanisms and possibly separate signalosome components.

4. Conclusion

The present data support a complex model of D\textsubscript{2} dopamine receptor-induced heterologous sensitization of AC5 where G\textsubscript{\alpha}s appears to directly interact with AC5. A role for G\textsubscript{\beta\gamma} was confirmed; however, our observations suggest an indirect role for G\textsubscript{\beta\gamma} that may be involved during the formation of the sensitization signaling complex. A critical role for AC5 in mediating dopamine responses has been previously demonstrated in AC5 deficient mice, which show impaired responses to D\textsubscript{2} receptor activation [9]. Therefore, these results have implications in brain regions where D\textsubscript{2} dopamine receptors and AC5 are coexpressed, such as the striatum [32], which is implicated in drug addiction, motivation, mood, and voluntary movement. Persistent D\textsubscript{2} dopa-
mine receptor activation has also been linked to psychiatric disorders (e.g., schizophrenia and drug abuse) and to the adaptive responses associated with drug therapy in Parkinson’s disease. Enhancing our understanding of the underlying components and mechanisms of heterologous sensitization and regulation of specific AC activity (in the striatum) may aid in the development of improved and future therapies for these disorders. For example, recent studies have identified small molecule inhibitors of Gβγ-mediated signaling [33] and AC isoform-specific inhibitors [34] that may offer novel therapeutic strategies for modulating complex CNS behaviors involving dopamine receptor signaling.

**Abbreviations**

AC: Adenylyl cyclase  
cAMP: Cyclic adenosine monophosphate  
CFP: Cyan fluorescent protein  
D2R: Dopamine D2L receptor  
GPCR: G protein-coupled receptor  
βARKct: β-adrenergic kinase c-terminus  
ER: Endoplasmic reticulum

**Acknowledgments**

This work was supported by Purdue University and by NIH grants MH060397 (V. J. Watts) and GM60419 (C. W. Dessauer). T. E. Hébert is a Chercheur National of the Fonds de la Recherche en Santé du Québec (FRSQ). The authors would like to thank Dr. Pierre-Alexandre Vidi for help with cloning of constructs. They would also like to thank Jason Conley and Elisabeth Garland-Kuntz for proofreading and making suggestions to improve the present paper.

**References**

[1] S. D. Iversen and L. L. Iversen, “Dopamine: 50 years in perspective,” Trends in Neurosciences, vol. 30, no. 5, pp. 188–193, 2007.

[2] B. Le Foll, A. Gallo, Y. L. Strat, L. Lu, and P. Gorwood, “Genetics of dopamine receptors and drug addiction: a comprehensive review,” Behavioural Pharmacology, vol. 20, no. 1, pp. 1–17, 2009.

[3] J.-M. Beaulieu and R. R. Gainetdinov, “The physiology, signaling, and pharmacology of dopamine receptors,” Pharmacological Reviews, vol. 63, no. 1, pp. 182–217, 2011.

[4] V. J. Watts and K. A. Neve, “Sensitization of adenylyl cyclase by Gaα5/o-coupled receptors,” Pharmacology and Therapeutics, vol. 106, no. 3, pp. 405–421, 2005.

[5] J. A. Chester, A. J. Mullins, C. H. Nguyen, V. J. Watts, and R. L. Meisel, “Repeated quinpirole treatments produce neurochemical sensitization and associated behavioral changes in female hamsters,” Psychopharmacology, vol. 188, no. 1, pp. 53–62, 2006.

[6] K. E. Calm, A. M. Lim, J. A. Onton, and R. P. Hammer, “Reduced Gi and Go protein function in the rat nucleus accumbens attenuates sensorimotor gating deficits,” Brain Research, vol. 982, no. 1, pp. 12–18, 2003.

[7] S. K. Sharma, W. A. Klee, and M. Nirenberg, “Dual regulation of adenylyl cyclase accounts for narcotic dependence and tolerance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 72, no. 8, pp. 3092–3096, 1975.

[8] X. Gao, R. Sadana, C. W. Dessauer, and T. B. Patel, “Conditional stimulation of type V and VI adenylyl cyclases by G protein β subunits,” Journal of Biological Chemistry, vol. 282, no. 1, pp. 294–302, 2007.

[9] K. W. Lee, J. H. Hong, I. Y. Choi et al., “Impaired D3 dopamine receptor function in mice lacking type 5 adenylyl cyclase,” Journal of Neuroscience, vol. 22, no. 18, pp. 7931–7940, 2002.

[10] T. Iwamoto, S. Okumura, K. Iwatsubo et al., “Motor dysfunction in type 5 adenylyl cyclase-null mice,” Journal of Biological Chemistry, vol. 278, no. 19, pp. 16936–16940, 2003.

[11] M. Bastepe, Y. Gunes, B. Perez-Villamil, J. Hunzelman, L. S. Weinstein, and H. Jüppner, “Receptor-mediated adenylyl cyclase activation through XLαα, the extra-large variant of the stimulatory G protein α-subunit,” Molecular Endocrinology, vol. 16, no. 8, pp. 1912–1919, 2002.

[12] T. A. Vortherms, C. H. Nguyen, M. Bastepe, H. Jüppner, and V. J. Watts, “D3 dopamine receptor-induced sensitization of adenylyl cyclase type 1 is Gas independent,” Neuropharmacology, vol. 50, no. 5, pp. 576–584, 2006.

[13] P. B. Wedegaertner, D. H. Chu, P. T. Wilson, M. J. Levis, and H. R. Bourne, “Palmitoylation is required for signaling functions and membrane attachment of Gαq and Gαsα,” Journal of Biological Chemistry, vol. 268, no. 33, pp. 25001–25008, 1993.

[14] D. S. Evanko, M. M. Thiyagarajan, D. P. Siderovski, and P. B. Wedegaertner, “Gβγ isoforms selectively rescue plasma membrane localization and palmitoylation of mutant Gaq and Gas,” Journal of Biological Chemistry, vol. 276, no. 26, pp. 23945–23953, 2001.

[15] D. J. Dupré, M. Robitaille, R. V. Rebois, and T. E. Hébert, “The role of Gβγ subunits in the organization, assembly, and function of GPCR signaling complexes,” Annual Review of Pharmacology and Toxicology, vol. 49, pp. 31–56, 2009.

[16] P. Crespo, T. G. Cachero, N. Xu, and J. S. Gutkind, “Dual effect of β-adrenergic receptors on mitogen-activated protein kinase. Evidence for a βγ-dependent activation and a Ga(s)-cAMP-mediated inhibition,” Journal of Biological Chemistry, vol. 270, no. 42, pp. 25259–25265, 1995.

[17] D. J. Dupré, M. Robitaille, N. Ethier, L. R. Villeneuve, A. M. Mamarbachi, and T. E. Hébert, “Seven transmembrane receptor core signaling complexes are assembled prior to plasma membrane trafficking,” Journal of Biological Chemistry, vol. 281, no. 45, pp. 34561–34573, 2006.

[18] R. Sadana, N. Dascal, and C. W. Dessauer, “N terminus of type 5 adenylyl cyclase scaffolds Gs heterotrimer,” Molecular Pharmacology, vol. 76, no. 6, pp. 1256–1264, 2009.

[19] M. Robitaille, N. Ramakrishnan, A. Baragli, and T. E. Hébert, “Intracellular trafficking and assembly of specific Kir3 channel/G protein complexes,” Cellular Signalling, vol. 21, no. 4, pp. 488–501, 2009.

[20] T. R. Hynes, S. M. Merveine, E. A. Yost, J. L. Sabo, and C. H. Berlot, “Live cell imaging of Gs and the β2-adrenergic receptor demonstrates that both as and β 1γ7 internalize upon stimulation and exhibit similar trafficking patterns that differ from that of the β2-adrenergic receptor,” Journal of Biological Chemistry, vol. 279, no. 42, pp. 44101–44112, 2004.

[21] D. S. Evanko, M. M. Thiyagarajan, and P. B. Wedegaertner, “Interaction with Gβγ is required for membrane targeting and palmitoylation of Ga(s) and Ga(q),” Journal of Biological Chemistry, vol. 275, no. 2, pp. 1327–1336, 2000.

[22] J. A. Przybyla and V. J. Watts, “Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L recep-
tor heterodimers,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 332, no. 3, pp. 710–719, 2009.

[23] V. J. Watts, R. Taussig, R. L. Neve, and K. A. Neve, “Dopamine D2 receptor-induced heterologous sensitization of adenylyl cyclase requires Gas: characterization of Gas-insensitive mutants of adenylyl cyclase V,” *Molecular Pharmacology*, vol. 60, no. 6, pp. 1168–1172, 2001.

[24] G. Zimmermann, D. Zhou, and R. Taussig, “Genetic selection of mammalian adenylyl cyclases insensitive to stimulation by G(αs),” *Journal of Biological Chemistry*, vol. 273, no. 12, pp. 6968–6975, 1998.

[25] C. H. Nguyen and V. J. Watts, “Dexras1 blocks receptor-mediated heterologous sensitization of adenylyl cyclase 1,” *Biochemical and Biophysical Research Communications*, vol. 332, no. 3, pp. 913–920, 2005.

[26] T. Avidor-Reiss, I. Nevo, R. Levy, T. Pfeuffer, and Z. Vogel, “Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of G(βγ),” *Journal of Biological Chemistry*, vol. 271, no. 35, pp. 21309–21315, 1996.

[27] S. Weitmann, G. Schultz, and C. Kleuss, "Adenylyl cyclase type II domains involved in G(βγ) stimulation,” *Biochemistry*, vol. 40, no. 36, pp. 10853–10858, 2001.

[28] A. Baragli, M. L. Grieco, P. Trieu, L. R. Villeneuve, and T. E. Hébert, “Heterodimers of adenylyl cyclases 2 and 5 show enhanced functional responses in the presence of Gas,” *Cellular Signalling*, vol. 20, no. 3, pp. 480–492, 2008.

[29] D. J. Dupré and T. E. Hébert, “Biosynthesis and trafficking of seven transmembrane receptor signalling complexes,” *Cellular Signalling*, vol. 18, no. 10, pp. 1549–1559, 2006.

[30] D. J. Dupré, A. Baragli, R. V. Rebois, N. Éthier, and T. E. Hébert, "Signalling complexes associated with adenylyl cyclase II are assembled during their biosynthesis,” *Cellular Signalling*, vol. 19, no. 3, pp. 481–489, 2007.

[31] R. V. Rebois, M. Robitaille, C. Gâlès et al., “Heterotrimeric G proteins form stable complexes with adenylyl cyclase and Kir3.1 channels in living cells,” *Journal of Cell Science*, vol. 119, no. 13, pp. 2807–2818, 2006.

[32] P. D. Gortari and G. Mengod, “Dopamine D1, D2 and mu-opioid receptors are co-expressed with adenylyl cyclase 5 and phosphodiesterase 7B mRNAs in striatal rat cells,” *Brain Research*, vol. 1310, pp. 37–45, 2010.

[33] A. L. Dessal, R. Prades, E. Giralt, and A. V. Smrcka, “Rational design of a selective covalent modifier of G protein βγ subunits,” *Molecular Pharmacology*, vol. 79, no. 1, pp. 24–33, 2011.

[34] H. Wang, H. Xu, L. J. Wu et al., "Identification of an adenylyl cyclase inhibitor for treating neuropathic and inflammatory pain,” *Science Translational Medicine*, vol. 3, no. 65, article 65ra3, 2011.